Literature DB >> 24551288

Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast.

Hua Zhao1, Daozhen Chen1, Jiayuan Wang1, Yongxiang Yin1, Qiong Gao2, Ye Zhang2.   

Abstract

FoxD3 is a transcription factor of the forkhead gene family. We investigated its expression in invasive ductal carcinomas (IDC) of the breast and its association with metastasis. The expression of FoxD3, human epidermal growth factor receptor-2 (HER-2), estrogen receptor (ER), progesterone receptor (PR) and Ki67 was examined by immunohistochemistry in samples from 121 patients with IDC. Non-tumorous breast adenosis tissues served as controls. HER2 expression was confirmed by fluorescence in situ hybridization (FISH). The expression levels of FoxD3 in IDC tissues and the breast cancer cell lines MCF-7 and MDA-MB-231 were additionally measured by western blotting. A greater percentage of total IDC patients and patients with lymph node metastases showed reduced FoxD3 expression compared to adenosis controls (p<0.05). Overall, FoxD3 was associated with metastatic status of IDC but not with age, pathological or clinical staging, or status of HER-2, ER, or PR. In particular, FoxD3 protein expression was down-regulated in the tumor epithelia of IDC samples from patients with metastases. Furthermore, FoxD3 protein expression was decreased in the metastatic MDA-MB-231 breast cancer cell line relative to the non-metastatic cell line, MCF-7. A greater number of patients with invasive, triple-negative breast cancer were also negative for FoxD3 expression than in other, non-triple-negative tumor types. These results suggest an inverse relationship between FoxD3 expression and tumor metastasis and warrants further investigation.

Entities:  

Keywords:  Breast cancer; FoxD3; HER-2; invasive ductal carcinomas

Mesh:

Substances:

Year:  2014        PMID: 24551288      PMCID: PMC3925912     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Requirement for Foxd3 in maintaining pluripotent cells of the early mouse embryo.

Authors:  Lynn A Hanna; Ruth K Foreman; Illya A Tarasenko; Daniel S Kessler; Patricia A Labosky
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

2.  A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal.

Authors:  Guangjin Pan; Jun Li; Yali Zhou; Hui Zheng; Duanqing Pei
Journal:  FASEB J       Date:  2006-06-21       Impact factor: 5.191

3.  Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells.

Authors:  J Sutton; R Costa; M Klug; L Field; D Xu; D A Largaespada; C F Fletcher; N A Jenkins; N G Copeland; M Klemsz; R Hromas
Journal:  J Biol Chem       Date:  1996-09-20       Impact factor: 5.157

4.  FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis.

Authors:  Corina A Schmid; Anne Müller
Journal:  Gastroenterology       Date:  2012-11-16       Impact factor: 22.682

5.  N-cadherin expression in breast cancer: correlation with an aggressive histologic variant--invasive micropapillary carcinoma.

Authors:  Chandandeep Nagi; Mitchell Guttman; Shabnam Jaffer; Rui Qiao; Rinat Keren; Aymara Triana; Maomi Li; James Godbold; Ira J Bleiweiss; Rachel B Hazan
Journal:  Breast Cancer Res Treat       Date:  2005-12       Impact factor: 4.872

6.  Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma.

Authors:  Uche I Ezeh; Paul J Turek; Renee A Reijo; Amander T Clark
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

7.  FOXD3 regulates migration properties and Rnd3 expression in melanoma cells.

Authors:  Pragati Katiyar; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2011-04-08       Impact factor: 5.852

8.  Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.

Authors:  Sijin Liu; Robert H Goldstein; Ellen M Scepansky; Michael Rosenblatt
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

Review 9.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy.

Authors:  Madhuri Kakarala; Max S Wicha
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

10.  Regulation of embryonic stem cell self-renewal and pluripotency by Foxd3.

Authors:  Ying Liu; Patricia A Labosky
Journal:  Stem Cells       Date:  2008-07-24       Impact factor: 6.277

View more
  11 in total

Review 1.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

2.  FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer.

Authors:  Shubhashish Sarkar; Malaney R O'Connell; Yoshinaga Okugawa; Brian S Lee; Yuji Toiyama; Masato Kusunoki; Robert D Daboval; Ajay Goel; Pomila Singh
Journal:  Mol Cancer Res       Date:  2017-08-29       Impact factor: 5.852

3.  Decreased FOXD3 Expression Is Associated with Poor Prognosis in Patients with High-Grade Gliomas.

Authors:  Wei Du; Changhe Pang; Dongliang Wang; Qingjun Zhang; Yake Xue; Hongliang Jiao; Lei Zhan; Qian Ma; Xinting Wei
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Mechanism of Regulatory Effect of MicroRNA-206 on Connexin 43 in Distant Metastasis of Breast Cancer.

Authors:  Zi-Jing Lin; Jia Ming; Lu Yang; Jun-Ze Du; Ning Wang; Hao-Jun Luo
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

5.  FOXD3 may be a new cellular target biomarker as a hypermethylation gene in human ovarian cancer.

Authors:  Gui-Fang Luo; Chang-Ye Chen; Juan Wang; Hai-Yan Yue; Yong Tian; Ping Yang; Yu-Kun Li; Yan Li
Journal:  Cancer Cell Int       Date:  2019-02-28       Impact factor: 5.722

6.  Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance.

Authors:  Fang Tai; Kunxiang Gong; Kai Song; Yanling He; Jian Shi
Journal:  Nat Commun       Date:  2020-01-14       Impact factor: 14.919

7.  Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells.

Authors:  Liang Gao; Kunwei Shen; Ni Yin; Min Jiang
Journal:  Front Oncol       Date:  2020-11-24       Impact factor: 6.244

8.  NUDT2 Disruption Elevates Diadenosine Tetraphosphate (Ap4A) and Down-Regulates Immune Response and Cancer Promotion Genes.

Authors:  Andrew S Marriott; Olga Vasieva; Yongxiang Fang; Nikki A Copeland; Alexander G McLennan; Nigel J Jones
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

9.  Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cells.

Authors:  Jia Ming; Yan Zhou; Junze Du; Shenghao Fan; Beibei Pan; Yinhuan Wang; Lingjun Fan; Jun Jiang
Journal:  Biosci Rep       Date:  2015-08-17       Impact factor: 3.840

10.  FOXD3 regulates anaplastic thyroid cancer progression.

Authors:  Huabin Yin; Tong Meng; Lei Zhou; Feixing Zhao; Xiufang Li; Yundong Li; Mengjun Hu; Haiyan Chen; Dianwen Song
Journal:  Oncotarget       Date:  2017-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.